88 related articles for article (PubMed ID: 38604812)
1. MUC16: clinical targets with great potential.
Zhang XY; Hong LL; Ling ZQ
Clin Exp Med; 2024 May; 24(1):101. PubMed ID: 38758220
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
3. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
4. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract][Full Text] [Related]
10. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
Bax HJ; Chauhan J; Stavraka C; Santaolalla A; Osborn G; Khiabany A; Grandits M; López-Abente J; Palhares LCGF; Chan Wah Hak C; Robinson A; Pope A; Woodman N; Naceur-Lombardelli C; Malas S; Coumbe JEM; Nakamura M; Laddach R; Mele S; Crescioli S; Black AM; Lombardi S; Canevari S; Figini M; Sayasneh A; Tsoka S; FitzGerald K; Gillett C; Pinder S; Van Hemelrijck M; Kristeleit R; Ghosh S; Montes A; Spicer J; Karagiannis SN; Josephs DH
Br J Cancer; 2023 Jan; 128(2):342-353. PubMed ID: 36402875
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
Front Immunol; 2022; 13():940801. PubMed ID: 36119108
[TBL] [Abstract][Full Text] [Related]
13. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft LE; Dangaj Laniti D; Coukos G
Nat Rev Cancer; 2022 Nov; 22(11):640-656. PubMed ID: 36109621
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
15. MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer.
Li Y; Tian W; Zhang H; Zhang Z; Zhao Q; Chang L; Lei N; Zhang W
Front Oncol; 2022; 12():830570. PubMed ID: 35692779
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]